Relying on the particularly high specificity displayed by antibodies, enzyme immunoassays have proved to be one of the most efficient tools for early detection of the catalytic activities displayed by antibodies. We took advantage of such an assay, namely the Cat-enzyme-linked immunoassay (EIA) approach developed in our laboratories, both to exhibit and characterise an antibody-catalysed thioacetal hydrolysis. Monoclonal antibody (mAb) H3-32 was thus identified to accelerate the hydrolysis reaction of thioacetal substrate (NC9) to vanillylmandelic acid (VMA), with a k(cat) of 0.148 h(-1) (k(uncat) = 6.85 x 10(-5) h(-1)), and a K(M) of 720 microM. Taking advantage of the enantiomeric discrimination between (R)- and (S)-VMA displayed by some of the anti-H3 monoclonal antibodies, we were also able to determine that (S)-VMA was preferentially formed during this abzymatic hydrolysis with a 47% enantiomeric excess. All these EIA measurements were confirmed through HPLC analyses.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0022-1759(02)00230-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Biomarkers.
Alzheimers Dement
December 2024
Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Background: The nuclear clearance and cytoplasmic aggregation of splicing repressor TAR DNA/RNA-binding protein-43 (TDP-43) occur in approximately 50% of Alzheimer's disease (AD) cases and about 45% of frontotemporal dementia (FTD). However, it is not clear how early such mechanism occurs in AD and FTD as there is no method of detecting TDP-43 dysregulation in living individuals. Since the loss of nuclear TDP-43 leads to cryptic exon inclusion, we propose that cryptic exon-encoded peptides may be detected in patient biofluids as biomarkers of TDP-43 loss of function.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.
Background: The prevalence of Alzheimer's disease (AD) is increasing worldwide, particularly in low- to middle-income countries (LMICs). Resource limitations and time constraints in many LMICs make AD screening and diagnosis difficult in the clinical setting. Neurodegenerative biomarkers in human tears may be associated with neurodegenerative diseases, but its potential has yet to be investigated in AD.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
ADEL Institute of Science & Technology (AIST), ADEL, Inc., Seoul, Korea, Republic of (South).
Background: While numerous blood biomarkers have been proposed for Alzheimer's disease (AD), only a few have demonstrated definitive diagnostic value. Recently, a set of phosphorylated Tau proteins, particularly pT217, have emerged as promising candidates with superior diagnostic performance. Given the development of pT217 antibodies by major global pharmaceutical companies, our goal is to create the best-in-class pT217 antibody, establishing it as the gold standard for diagnostics.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
Osaka University Graduate School of Medicine, Toyonaka, Japan.
Background: We have developed a technology for isolating extracellular vesicles (EVs) released from the central nervous system present in plasma.
Method: Initially, we differentiated induced pluripotent stem cells (iPS) into neurons to examine the membrane surface molecules of neuron-derived EVs in culture media. Our analysis revealed a specific interest in neuron-specific APLP1.
Background: Alzheimer's Disease (AD) is a major neurodegenerative disorder characterized by amyloid deposits in brain tissues and representing a continuously increasing global burden in need of disease-modifying therapeutic options. Amyloid beta 1-42 and 1-40 peptides and the amyloid beta 1-42/1-40 ratio are hallmarks of AD and are commonly monitored in Cerebro-Spinal Fluid (CSF) along other AD biomarkers, to support diagnosis and management of AD patients. Over the past few years, blood-based AD biomarkers have emerged as highly relevant and more practical alternatives to CSF biomarkers, and further technical performance characterization of the associated assays would be beneficial to the AD research and medical community.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!